NEW DELHI: AstraZeneca Pharma India has obtained permission to import on the market and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL answer for infusion from the Central Drugs Standard Control Organisation (CDSCO), topic to the receipt of associated statutory approvals.
“Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements”, says an organization assertion.
According to GLOBOCAN 2022 information, lung cancer stays the fourth most typical reason for cancer-related mortality in India. Around 15% of sufferers with NSCLC in India have resectable illness representing a big affected person inhabitants.
